Pankreas Karsinomu Nedeniyle Ameliyat Edilen Hastalarda Serum CA 19-9 Düzeyleri ile Tümörün Lenfovasküler ve Perinöral İnvazyonu ve Lenf Nodu Metastazı Arasındaki İlişki
Abstract
Objectives: The aim of this study was to determine the relationship between serum CA 19-9 levels and lymphovascular and perineural invasion and lymph node metastasis in patients operated due to pancreatic cancer.
Materials and Methods: A total of 32 patients underwent pancreaticoduodenectomy or distal pancreatectomy at Sivas Cumhuriyet University Department of Surgical Oncology. CA 19-9 values were evaluated by retrospectively examining the data of the patients. By examining the pathology reports, the presence of lymphovascular and perineural invasion and lymph node metastasis was evaluated.
Results: The mean serum CA 19-9 level in patients with lymphovascular invasion was 242.38 U/mL, and the mean serum CA 19-9 level in patients without lymphovascular invasion was 31.73 U/mL. The mean serum CA 19-9 level was 220.93 U/mL in patients with perineural invasion and 15.23 U/mL in patients without perineural invasion. The mean serum CA 19-9 level was 238.52 U/mL in patients with lymph node metastasis and 35.16 U/ mL in patients without lymph node metastasis. A value of 16.25 U/mL of serum CA 19-9 gives a positive result of 84.7% for lymphovascular invasion and 91.8% for perineural invasion. A value of 27.06 U/mL of serum CA 19-9 gives a positive result of 85.9% for lymph node metastasis.
Conclusion: Lymphovascular invasion was detected in 94.44% and perineural invasion was detected in 90.48% of our patients with serum CA19- 9 values above 16.25 U/mL. Lymph node metastasis was detected in 80.7% of our patients with serum CA19-9 values above 27.06 U/mL. Before surgery, it is important to predict the probability of lymphovascular and perineural invasion of the tumor and lymph node metastasis, and to make the decision to perform broader surgery and perform adjuvant, neoadjuvant therapy and serum CA19-9 levels are of great benefit in this regard
Keywords
: Pancreatic Cancer, CA 19-9, Lymphovascular And Perineural Invasion
Ethical Statement
Ethics Committee Approval: Ethics committee approval of the study was obtained from Sivas Cumhuriyet University Clinical Research Ethics Committee with the decision numbered 2020-10/34.
Informed Consent: We have received verbal consent from patients.
Peer-review: Externally peer-reviewed. Authorship Contributions Surgical and Medical Practices: M.E.B., M.C.M., K.K., Concept: M.E.B., M.C.M., K.K., Design: M.E.B., M.C.M., K.K., Data Collection or Processing: M.E.B., M.C.M., K.K., Analysis or Interpretation:
M.E.B., M.C.M., K.K., Literature Search: M.E.B., M.C.M., K.K.,
Writing: M.E.B., M.C.M., K.K.
Conflict of Interest: We declare that there is no conflicts of interest associated with this publication.
Financial Disclosure: We declare that we have not received any financial support to perform this study
References
- 1. American Cancer Society. Cancer facts & figures 2014. Atlanta, Georgia: American Cancer Society; 2014. acspc-042151.pdf. Accessed March 28 2014.
- 2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
- 3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
- 4. Howlader N, Noone AM, Krapcho M, et al. Cancer Statistics Review, 1975- 2012 - SEER Statistics. National Cancer Institute. Bethesda, MD. https://seer. cancer.gov/archive/csr/1975_2012/
- 5. Muniraj T, Jamidar PA, Aslanian HR. Pancreatic cancer: a comprehensive review and update. Dis Mon. 2013;59:368-402.
- 6. Boone BA, Steve J, Zenati MS, et al. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol. 2014;21:4351-4358.
- 7. Ito S, Gejyo F. Elevation of serum CA19-9 levels in benign diseases. Intern Med. 1999;38:840-841.
- 8. Fujioka S, Misawa T, Okamoto T, et al. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg. 2007;14:539-544.
- 9. Meyer W, Jurowich C, Reichel M, et al. Pathomorphological and histological prognostic factors in curatively resected ductal adenocarcinoma of the pancreas. Surg Today. 2000;30:582-587.
- 10. Kayahara M, Nagakawa T, Ohta T, et al. Surgical strategy for carcinoma of the papilla of Vater on the basis of lymphatic spread and mode of recurrence. Surgery. 1997;121:611-617.